Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics, with news centered on its approved medicines, TTR franchise, clinical pipeline and financial performance. Company updates commonly address AMVUTTRA/vutrisiran and ONPATTRO/patisiran for transthyretin-mediated amyloidosis, GIVLAARI/givosiran for acute hepatic porphyria, OXLUMO/lumasiran for primary hyperoxaluria type 1, and partner-commercialized RNAi medicines.
Recurring developments include quarterly product revenue reports, guidance, clinical and real-world data for ATTR-CM and other cardiovascular programs, pipeline progress across cardio-metabolic disease, neuroscience and hematology, disease-awareness collaborations, and investor conference presentations. Alnylam also reports on its Alnylam 2030 strategy and commercialization of RNAi medicines in global markets.
Alnylam Pharmaceuticals (Nasdaq: ALNY) reported Q2 2026 total revenues of $1.29 billion, up 67% year over year, with total net product revenues of $1.17 billion, up 74%. GAAP income from operations was $231 million versus a loss a year ago, and GAAP net income reached $164 million.
Growth was led by total TTR revenues of $1.03 billion (up 89%), including AMVUTTRA revenue of $1.01 billion (up 106%), while ONPATTRO declined 65%. Rare disease products GIVLAARI and OXLUMO delivered $142 million, up 11%. Alnylam revised 2026 TTR revenue guidance to $4.2–$4.5 billion from $4.4–$4.7 billion.
The company highlighted positive HELIOS-B vutrisiran data in ATTR-CM, initiated Phase 2 studies for ALN-6400 and mivelsiran, advanced multiple neurology programs, expanded AI collaborations with Inceptive and Komodo Health, and signed an exclusive AMVUTTRA commercialization agreement with BeOne Medicines in China, subject to marketing authorization.
Alnylam (Nasdaq: ALNY) will report its second quarter 2026 financial results, for the period ending June 30, 2026, on Thursday, July 30, 2026, before U.S. markets open. Management will host a conference call and live audio webcast at 8:30 a.m. ET to review results and future expectations, with live and archived access via the Investors section of the company website.
Alnylam (Nasdaq: ALNY) reported multiple advances in its neuroscience pipeline at AAIC 2026, centered on investigational RNAi therapeutics for Alzheimer’s disease and related disorders. The company initiated the global Phase 2 APPlauDS study of mivelsiran in Down syndrome–associated Alzheimer’s disease, and completed enrollment in the Phase 2 cAPPricorn‑1 study of mivelsiran in cerebral amyloid angiopathy, with initial results expected in 2028.
According to Alnylam, updated Phase 1 mivelsiran data in early-onset Alzheimer’s showed no evidence of increased ARIA risk, with mean maximum CSF reductions of ‑89.9% for sAPPβ and ‑70.2% for Aβ42 over up to 30 months. The most common adverse events were procedural pain and headache, with no serious or severe events related to study drug. Alnylam also highlighted preclinical data and the Phase 1 design for ALN‑5288, a tau-targeting RNAi therapeutic in collaboration with Regeneron.
Komodo Health expanded its strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY) to scale the Marmot AI analytics platform across Alnylam’s customer-facing and broader enterprise functions. Marmot, built on Komodo’s Healthcare Map of over 330 million de-identified patient journeys, supports real-time, reproducible healthcare intelligence.
Alnylam has integrated diverse enterprise datasets into Marmot, cutting reporting cycles from months to hours and enabling new AI-driven insights. Komodo also introduced new Marmot capabilities aimed at making trusted, verifiable intelligence accessible to business leaders, consultants, analysts, and data scientists across Life Sciences organizations.
Alnylam (Nasdaq: ALNY) will host its 10th “RNAi Roundtable” webcast series in 2026, featuring scientists, physicians, and medical thought leaders.
Sessions will cover ALN-6400 for bleeding disorders, zilebesiran for blood pressure, and ALN-HTT02 for Huntington’s disease, with live webcasts and online replays.
Summary not available.
Alnylam (Nasdaq: ALNY) and Inceptive announced a strategic AI collaboration to speed discovery of RNAi therapeutics. The alliance is valued at up to $2 billion, with $30 million in upfront cash and equity and additional preclinical, regulatory, and commercial milestone payments.
By integrating Inceptive’s generative AI foundation models with Alnylam’s RNAi platform and 20+ years of proprietary siRNA data, the partners aim to enhance siRNA design, prioritize top candidates, and support Alnylam’s Alnylam 2030 pipeline expansion strategy.
Alnylam (Nasdaq: ALNY) released its 2025 Corporate Responsibility Report outlining progress across six pillars: Patients, Science, Employees, Communities, Environment & Operations, and Governance & Integrity.
Highlights include a 2030 Scope 1–2 GHG reduction framework, expanded global patient access support, and a $2 million, two-year Alnylam Challengers philanthropy commitment.
Alnylam (Nasdaq: ALNY) reported new HELIOS-B Phase 3 analyses of vutrisiran in ATTR-CM at Heart Failure 2026. Vutrisiran reduced all-cause mortality and recurrent cardiovascular events in patients with atrial fibrillation and showed consistent benefit across low SBP, high comorbidity, women, and those on background therapies.
A pooled safety analysis over 25,000 patient-years of TTR-silencing RNAi therapies found low, placebo-comparable rates of vitamin A deficiency-related ocular events and no clinically meaningful vitamin A deficiency. The DemonsTTRate real-world study will follow >2,000 ATTR-CM patients for up to five years.
Alnylam (Nasdaq: ALNY) said management will present company overviews at two investor conferences: BofA Securities Healthcare on May 13, 2026 at 10:40 am PT (1:40 pm ET) in Las Vegas, and Goldman Sachs Annual Healthcare on June 9, 2026 at 11:20 am ET in Miami.
A live audio webcast will be available on the Investors section of the company website, with replays posted within 48 hours after each event.